{"analyses":[{"ciLowerLimit":"0.57","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.03","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.0810","paramType":"Hazard Ratio (HR)","paramValue":"0.77","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"48.5","upperLimit":"87.8","value":"65.6"},{"comment":"Data could not be estimated due to higher (\\>50%) number of censored participants.","groupId":"OG001","lowerLimit":"71.1","upperLimit":"NA","value":"88.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"204"}],"units":"Participants"}],"description":"OS was defined as the time between the date of randomization and the date of death from any cause. OS was estimated using Kaplan-Meier method and 95% CI for median was computed using the method of Brookmeyer and Crowley.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Bendamustine 120 mg/m\\^2 IV infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.","id":"OG000","title":"Bendamustine Alone"},{"description":"Induction phase: Participants received Bendamustine 90 mg/m\\^2 IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants also received obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6. Maintenance phase: Participants with CR, PR or SD then received obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurred first).","id":"OG001","title":"Obinutuzumab + Bendamustine"}],"paramType":"MEDIAN","populationDescription":"ITT population.","reportingStatus":"POSTED","timeFrame":"Baseline until death (up to 8.5 years overall)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}